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Abstract
Background: Tick-borne encephalitis virus (TBEV) is one of the most important flaviviruses that targets the central
nervous system (CNS) and causes encephalitides in humans. Although neuroinflammatory mechanisms may
contribute to brain tissue destruction, the induction pathways and potential roles of specific chemokines in
TBEV-mediated neurological disease are poorly understood.
Methods: BALB/c mice were intracerebrally injected with TBEV, followed by evaluation of chemokine and
cytokine profiles using protein array analysis. The virus-infected mice were treated with the CC chemokine
antagonist Met-RANTES or anti-RANTES mAb to determine the role of RANTES in affecting TBEV-induced neurological
disease. The underlying signaling mechanisms were delineated using RANTES promoter luciferase reporter assay,
siRNA-mediated knockdown, and pharmacological inhibitors in human brain-derived cell culture models.
Results: In a mouse model, pathological features including marked inflammatory cell infiltrates were observed in brain
sections, which correlated with a robust up-regulation of RANTES within the brain but not in peripheral tissues and
sera. Antagonizing RANTES within CNS extended the survival of mice and reduced accumulation of infiltrating cells
in the brain after TBEV infection. Through in vitro studies, we show that virus infection up-regulated RANTES
production at both mRNA and protein levels in human brain-derived cell lines and primary progenitor-derived
astrocytes. Furthermore, IRF-3 pathway appeared to be essential for TBEV-induced RANTES production. Site mutation of
an IRF-3-binding motif abrogated the RANTES promoter activity in virus-infected brain cells. Moreover, IRF-3 was
activated upon TBEV infection as evidenced by phosphorylation of TBK1 and IRF-3, while blockade of IRF-3 activation
drastically reduced virus-induced RANTES expression.
Conclusions: Our findings together provide insights into the molecular mechanism underlying RANTES production
induced by TBEV, highlighting its potential importance in the process of neuroinflammatory responses to TBEV
infection.
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Background
Tick-borne encephalitis (TBE), an endemic in many
regions of Europe and Asia, is an important emerging
infectious disease that targets the central nervous system
(CNS) caused by the TBE virus (TBEV; family Flaviviridae,
genus Flavivirus). TBEV consists of three subtypes: the
European subtype (TBEV-Eu) in most parts of Europe;
Siberian subtype in eastern Europe, Russia, and northern
Asia; and Far Eastern subtype (TBEV-FE) in eastern
Russia and some parts of China and Japan. TBEV-Eu is
mainly transmitted by Ixodes ricinus and the other two
subtypes by Ixodes persulcatus [1]. In humans, TBEV
causes a variety of clinical manifestations, ranging from
flu-like febrile disease to encephalitis of differing severity
levels [2]. The clinical outcome may in part depend upon
the subtype of TBEV infection. TBEV-Eu and TBEV-Sib
subtypes are usually associated with milder disease, with
mortality rates of 0.5–2 %. In contrast, infection with the
TBEV-FE subtype results in the most severe CNS disorder,
with mortality rates of up to 40 % and higher rates of se-
vere neurologic sequelae [3, 4].
The first TBEV replication usually occurs in dendritic
cells of the skin following tick bites, later in regional
lymph nodes, and then virus can be detected in plasma
[5, 6]. During the stage of active viremia, virus may cross
the blood-brain barrier (BBB) and invade the CNS where
it causes profound destruction of nerve cells [2]. The
most severe forms of TBE may be characterized by
major damage to neurons in different parts of the brain
and spinal cord [4]. Generally, CNS pathology is the
consequence of viral infection of corresponding cells and
the resulting neuroinflammatory responses. In clinical
studies, common findings include immunohistochemical
staining of TBEV antigen in large neurons of human
brains of fatal cases with relatively short natural clinical
course. However, topographical correlation between
inflammatory changes and distribution of viral antigens is
poor, since affected regions with prominent inflammatory
infiltrates and marked neuronal damage contained only
few immunolabeled structures [7]. Furthermore, it was
found that granzyme B-releasing cytotoxic T cells contrib-
ute significantly to neuronal damage in human TBE [8],
supporting the notion that liberation of inflammatory
mediators and recruitment of cytotoxic T cells may con-
tribute to nerve cell dysfunction in human TBEV infec-
tion. In a TBEV-infected mouse model, CD8+ T cells was
also shown to play a pivotal role in the immunopathology
of TBE as evidenced by prolonged survival of severe com-
bined immunodeficiency (SCID) or CD8−/− mice following
infection, compared with immunocompetent mice or mice
with adoptively transferred CD8+ T cells [9].
These results imply that immunopathological effects
significantly contribute to the onset of TBE. However, the
exact mechanisms of proinflammatory effects responsible
for immune-mediated neuronal injury are still unclear
with limited data available on the role of chemoattractant
cytokines (chemokines) during TBEV infection. Although
proinflammatory chemokines C-X-C motif chemokine 10
(CXCL10), C-X-C motif chemokine 11 (CXCL11), mono-
cyte chemoattractant protein-1 (MCP-1), and regulated
upon activation, normal T cell expressed, and presumably
secreted (RANTES) have been detected in the cerebro-
spinal fluid (CSF) samples of TBE patients [10–14], the
specific impact on inflammatory responses and the mo-
lecular mechanisms that regulate chemokine expression
remain to be further addressed.
Chemokines constitute a family of small, secreted
proteins that orchestrate leukocyte migration to sites of
inflammation, playing a crucial role in the regulations of
homeostasis by trafficking specific cells under physio-
logic conditions [15, 16]. However, overproduction of
chemokines in response to immunologic, inflammatory,
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infectious signals may elicit deleterious effects, especially
in the largely non-self-renewing brain tissues [17].
Therefore, a clearer understanding of how chemokines
impact the inflammatory response to viral infections
within the CNS is important for identifying targets that
can potentially be manipulated for the development of
host defense with minimal negative effects. To date,
there is limited information concerning specific chemo-
kines responsible for cell recruitment and their potential
impact on disease progression during TBEV infection.
In the present study, we have evaluated chemokine
expression profiles within CNS after TBEV infection
using mouse as a model. We demonstrate that TBEV in-
duces marked inflammatory cell infiltrates in the brain.
RANTES has been shown to be one of the main chemo-
kines induced within CNS during primary TBEV infection
[12, 14]. Blockade of RANTES reduces the accumulation
of infiltrating cells and extends the survival of mice after
TBEV infection. Furthermore, our data indicate that
stimulation of interferon regulatory factor 3 (IRF-3) path-
way leads to RANTES secretion by TBEV-infected human
brain-derived cells. Together, our results identify RANTES
as a potential mediator of the neuroinflammatory re-
sponses seen in TBEV infection, providing basic insights
into the molecular mechanism underlying TBEV-induced
RANTES production.
Methods
Ethics statement
All experimental procedures were conducted according
to the guidance of the Institutional Animal Care and
Use Committee of Wuhan Institute of Virology, Chinese
Academy of Sciences. All surgeries were performed
under sodium pentobarbital anesthesia, and all efforts
were made to minimize suffering as well as the number
of animals used.
Viruses and cell cultures
WH2012, a Far Eastern strain of TBEV, was isolated
from tick (I. persulcatus) samples and characterized as
previously described [18]. The nucleotide acid sequence
of WH2012 strain was deposited in the GenBank database
(accession number KJ755186). Working stocks of TBEV
were routinely propagated on Vero cells. All procedures
with infectious materials were performed under biosafety
level-3 (BSL-3) conditions.
BHK-21, Vero, SK-N-SH (a human neuroblastoma cell
line; ATCC HTB-11), and T98G (a human glioblastoma cell
line; ATCC CRL-1690) cells were cultured in Minimum
Essential Medium (MEM). CCF-STTG1 (a human astrocy-
toma cell line; ATCC CRL-1718) and THP-1 (a human
monocytic cell line; ATCC TIB-202) were grown in RPMI
1640 medium. A549 (a human alveolar epithelial cell line,
ATCC CCL-185) cells were cultured in F-12K medium. All
media were supplemented with 10 % fetal bovine serum,
2 mM L-glutamine, 100 U ml−1 penicillin and 100 mg ml−1
streptomycin (Life Technologies, NY). Human progenitor-
derived astrocytes (HPDAs) were generated from neural
progenitor cells and cultured as previously described
[19, 20]. Differentiation of THP-1 (2 × 105 cells/ml)
monocytes into macrophage-like cells was achieved using
200 nM phorbol 12-myristate 13-acetate (PMA; Sigma,
NY) for 3 days as previously described [21].
Mice infection and monitoring
Groups of 1-week-old BALB/c mice of either sex were
challenged with TBEV WH2012 by intraperitoneal (ip)
or intracerebral (ic) inoculation route with a volume of
20 μl of virus suspensions at various concentrations,
using Hamilton syringe (Hamilton Co., Switzerland).
Mock-infected animals were inoculated with 20 μl of
diluent (serum-free DMEM). Groups of female mice
aged 7–8 weeks were infected intracerebrally with 103
median tissue culture infective dose (TCID50)s of TBEV
WH2012. Mice were then monitored daily for signs of
neurological disease and survival over a period of 12 to
25 days. Mortality rate was assessed at the time points
indicated below.
Tissue isolation and preparation
Cohorts of virus-infected mice were sacrificed after ic
inoculation with a virus dose containing 103 TCID50s for
the time points indicated below. Whole blood was
obtained by cardiac puncture, and sera were separated
by centrifugation. Following perfusion with ice-cold
phosphate-buffered saline (PBS), the small intestine,
hind limb muscle, heart, lung, spleen, liver, and brain
were collected, homogenized, and cleared by low-speed
centrifugation. Then, sera and tissue samples were
immediately stored at −80 °C for further analysis.
Virus titration
Virus infectivity was determined by estimation of the
TCID50 using standard cell culture conditions. Briefly,
BHK-21 cells were seeded in 96-well plates. When the
cells reach 80 % confluence, they were infected with
150 μl of serial decimal dilutions of each sample for 4 days.
The cytopathic effect was thereby monitored by micro-
scopic examination, and the infectivity titer was expressed
as TCID50/g tissue using the Reed-Muench formula.
Histology
After anesthesia with sodium pentobarbital (60 mg kg−1),
mice were transcardially perfused with ice-cold PBS
followed by 4 % (w/v) paraformaldehyde (PFA) in PBS.
The brains were dissected and post-fixed overnight, then
trimmed, and routinely paraffin wax embedded. Serial 3–
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5-μm-thick sections were stained with hematoxylin-eosin
(HE) for histological analysis under a light microscopy.
Protein array analysis
Brains of mice were screened for 40 inflammatory fac-
tors using a commercialized mouse inflammation anti-
body (Ab) array C1 Kit according to the manufacturer’s
instructions (RayBiotech, Inc., Norcross, GA). Briefly,
brain sections were pooled (n = 4/group), homogenized
in lysis buffer (kit component), and then centrifuged at
12,000 rpm for 15 min at 4 °C. The membranes were
incubated with the supernatants at a final concentration
of 1 μg/μl. Chemiluminescent blot documentation was
performed with a FluorChem HD2 imaging system.
In vitro TBEV infection
T98G, CCF-STTG1, SK-N-SH, HPDAs, A549, and
differentiated THP-1 cells were infected with TBEV
WH2012 at a multiplicity of infection (MOI) of 1. To
assess the requirement for viral replication in the gener-
ation of RANTES, cells were treated with UV-inactivated
preparations of TBEV. At the indicated time points, cul-
ture supernatants and cell monolayers were harvested for
further analysis.
RANTES mRNA quantification
Total RNA was extracted from cell monolayers using
Omega HP total RNA Isolation kit (Omega Bio-Tek,
Inc., GA). To remove residual genomic DNA, RNA
samples were pretreated with RQ1 RNase-free DNase
(Promega, WI). Then, RNA was converted to cDNA using
M-MLV Reverse Transcriptase (Promega). Real-time PCR
was carried out using primers specific for human
RANTES (sense 5′-ACCACACCCTGCTGCTTTGC-3′,
antisense 5′-CCGAACCCATTTCTTCTCTGG-3′) and
TransStart Eco Green qPCR SuperMix kit (TransGen,
Beijing, China) on the Bio-Rad CFX96 Real-Time PCR
System (Bio-Rad Laboratories, Inc., CA). The data acquisi-
tion and analysis were carried out with CFX Manager
Software (version 2.1; Bio-Rad). Relative expression of
RANTES was calculated using the 2−ΔΔCt method [22]
after normalization with endogenous control β-actin
(sense 5′-CGGGAAATCGTGCGTGACAT-3′, antisense
5′-GAACTTTGGGGGATGCTCGC-3′). Results are
expressed as the relative fold increase of the stimulated
over the mock control group.
RANTES ELISA
The mouse tissue homogenates and cell culture superna-
tants were assessed for RANTES protein levels using
RANTES-specific enzyme-linked immunosorbent assay
(ELISA) kit (Boster, Wuhan, China), according to the
manufacturer’s instructions. The analytical procedure
has been described previously [20].
Chemotaxis
Cell chemotaxis assay was performed as previously
described [23, 24]. Briefly, THP-1 cells (5 × 105 cells/
100 μl) were added to the upper chamber of Transwell
insert (5-μm polycarbonate filter; Corning, NY). A total
of 1-ml culture supernatant from TBEV-infected T98G
(MOI = 5) for 72 h was added to the lower chamber of
Transwell insert. For the neutralizing experiment, anti-
hRANTES Ab (0.5 μg/ml; R&D Systems, Minneapolis,
MN) or control normal goat IgG was added to the
conditioned media in the lower chamber. Plates were
incubated for 4 h at 37 °C and 5 % CO2. Transwell
inserts were then removed, and the number of cells
migrated to the lower chamber was determined with a
TC20 Automated Cell Counter (Bio-Rad). Data are
expressed as percentage of the migrated cells in total
number of input cells.
Anti-RANTES treatment
Cohorts of mice were treated via ic injection with
Met-RANTES (1 μg/mouse; Bachem, Basel, Switzerland),
vehicle, anti-RANTES mAb (MAB478), or an IgG2a
isotype-matched control mAb (10 μg/mouse; R&D
Systems) on days 2 to 8 after ic infection with TBEV
WH2012 (103 TCID50s). Met-RANTES is a recombinant
RANTES analog, in which the initiating methionine resi-
due is retained after expression in Escherichia coli cells,
resulting in a potent antagonist of the murine RANTES
receptors CC chemokine receptor (CCR)5 and CCR1
[25, 26]. The chosen RANTES-neutralizing mAb reacts
with murine and human RANTES and no other identified
cytokine or chemokine [27, 28]. Mice were monitored
daily for signs of neurological disease and survival over a
period of 14 days. The survival curves were compared
using Kaplan-Meier tests. Both brain virus titers and mice
survival rates were estimated at the time points indicated
below. The severity of inflammation was determined by
staining sections of paraffin-embedded brain tissue with
HE by day 8 post infection (p.i.), as after this time, the
efficacy of this treatment may decline due to the decay of
corresponding molecules within the mouse brain.
Plasmids and cell transfection
The RANTES promoter reporter construct (pGL2-220)
and site-mutated plasmids for cAMP response element
(CRE) (CRE Mut), interferon-stimulated response element
(ISRE) (ISRE Mut), nuclear factor for interleukin 6 (NF-
IL6) (NF-IL6 Mut), nuclear factor kappa-light-chain-en-
hancer of activated B cells (NF-kB1) (NF-kB1 Mut), and
NF-kB2 (NF-kB2 Mut) were kindly given by Dr. Casola
(University of Texas Medical Branch, USA) [29]. The
dominant-negative mutants of IkB kinase alpha (mIkBα),
IRF-3ΔN, and IRF-7ΔN were kind gifts of Prof. S. B. Xiao
(Huazhong Agricultural University, China). All plasmids
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for transfection were prepared with Endo-free Plasmid
Midi Kit (Omega Bio-Tek, Inc., GA). Exponentially grow-
ing T98G cells in 24-well plates were transfected with
0.1 μg of pRL-TK reporter (Renilla luciferase for internal
control) and 0.5 μg of RANTES-pGL2 plasmids (Firefly
luciferase, experimental reporter) using the X-tremeGENE
HP reagent (Roche, Mannheim, Germany). For co-
expression experiments, 0.5 μg of each indicated expression
plasmid was added to the reporter vectors. Twenty-four
hours after transfection, cells were inoculated with TBEV
and harvested at the indicated time interval. Reporter gene
activity was measured using a dual-luciferase assay system
(Promega, Madison, WI), according to the manufacturer’s
instructions.
Western blot analysis
T98G cells were washed with PBS and lysed with RIPA
lysis buffer (Beyotime, Nantong, China) containing
protease inhibitor (cOmplete Protease Inhibitor Cocktail
Tablets; Roche). Equal amounts of protein were separated
on 12 % SDS-PAGE and transferred onto an Immobilon-P
PVDF membrane (Millipore, MA). The blots were blocked
for 1 h with 2 % bovine serum albumin in Tris-buffered
saline (20 mM Tris-HCl, pH 7.4, 0.15 M NaCl) containing
0.1 % Tween 20 (TBST) at room temperature (RT) and
reacted overnight at 4 °C with the primary antibodies. The
membranes were washed four times with TBST and then
incubated with the secondary Ab for 1 h at RT. Horserad-
ish peroxidase-conjugated goat anti-rabbit IgG (#31460)
or goat anti-mouse IgG (#31430) secondary antibodies
were used (Thermo Scientific Pierce, IL). The membranes
were washed and visualized with BeyoECL Plus Chemilu-
minescent Substrate (Beyotime) for signal detection.
Primary antibodies directed against p-IRF-3 (Ser396,
4D4G, #4947), p-TANK-binding kinase 1 (TBK1) (Ser172,
D52C2, #5483), retinoic acid-inducible gene 1 (RIG-I)
(D14G6, #3743), melanoma differentiation-associated pro-
tein 5 (MDA5) (D74E4, #5321), IkBα (#9242), and TBK1
(#3013) were obtained from Cell Signaling Technologies
(Beverly, MA). IRF-3 (#11312-1-AP) and β-actin (#60008-
1-Ig) antibodies were purchased from Proteintech Group,
Inc. (Chicago, IL).
RNA interference
T98G cells were transfected with small interfering RNA
(siRNA) duplexes using HiPerFect transfection reagent
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocols. siRNA oligonucleotides were synthe-
sized (RiboBio, Guangzhou, China) with the following
sequences (sense strands): RIG-I, 5′-GGAAGAGGUG-
CAGUAUAUU-3′; MDA5, 5′-GGUGAAGGAGCAGAU
UCAG-3′ [30]. Nonsilencing siRNA with a scrambled
sequence were used as a negative control (control siRNA
(Ctrl siRNA)). After cultured for 16 h, the medium with
transfection reagent was removed. Cells were either
mock treated or infected with TBEV at an MOI of 1 for
24 h. Culture supernatants and cell monolayers were
harvested for further analysis.
Inhibition of cellular signaling pathway
Inhibition of IRF-3 and NF-kB signaling in T98G and
CCF-STTG1 cells was performed with BX795 (InvivoGen,
CA) and MG132 (Millipore), respectively, as described
previously [31, 32]. Briefly, virus inoculation were carried
out as mentioned above, followed by treatment with
BX795 (2 μM), MG132 (3 μM), or DMSO vehicle in the
absence of serum for 36 h, and the levels of RANTES re-
leased in culture supernatants were determined by ELISA.
IRF-3 and p-IRF-3 were detected by Western blot analysis.
Virus infectivity was determined by TCID50 assay as
described above.
Statistical analyses
Data were expressed as means ± SD. All statistical ana-
lyses were carried out using SigmaPlot®10.0 software
(Stystat Software, CA), with a P value of <0.05 consid-
ered statistically significant.
Results
Virulence studies
After ic inoculation of 1-week-old mice with TBEV (103
TCID50s), most animals developed neurological symp-
toms, such as hunched posture, loss of balance, hind
limb paralysis, and convulsions in the final stage of the
disease prior to death (data not shown). Major organs
were harvested at various time points to determine virus
titers in mice infected with TBEV. Virus was initially
detected between 2 and 5 days p.i., with virus titers
peaking on day 8 p.i. except for small intestine and
heart. With respect to viral distribution, significantly
higher virus titers were recovered from the brain, but
relatively mediocre levels of viruses were also detected
in peripheral tissues (Fig. 1a). Following ic infection of
mice with sequentially increasing doses, all tested groups
exhibited fatal outcomes, with no significant differences
in the mean survival times between the challenge doses
(Fig. 1b). However, following ip (Fig. 1c), subcutaneous
(sc) [18] or intramuscular (im) (data not shown) infec-
tion of groups of mice with sequentially increasing
doses, 100 % mortality was not observed even with the
highest tested virus challenge dose. These observations
indicate that direct CNS infection induces early death in
mice even after low-dose challenge.
TBEV induces RANTES within host CNS
To gain insight into the neuroinflammatory responses
elicited specifically in the CNS compartment, TBEV
WH2012 strain was inoculated by the ic route. Time
Zhang et al. Journal of Neuroinflammation  (2016) 13:209 Page 5 of 18
course of acute brain injury was assessed histologically.
As depicted in Fig. 2, the HE-stained brain sections of
the cerebral cortex obtained from virus-infected group
indicate inflammatory cell infiltrates appeared as early as
3 days post challenge. By day 4 p.i., the inflammatory
reaction increased. Marked inflammatory cell infiltrates
were observed on day 8 p.i. when nearly all infected
mice succumbed to infection.
CNS infiltration of peripheral immune cells requires
antecedent local expression of cytokines, chemokines,
and cell adhesion molecules [33]. To identify the key
immune factors induced by TBEV in CNS, brains of
virus-infected mice were harvested on days 2, 5, and 8
p.i., and the expression of 40 inflammatory factors was
profiled by a mouse-specific protein array. Compared
with baseline expression in uninfected controls, the
secretion of a panel of immune factors was increased in
mouse brains after virus inoculation. Among them, the
CC-chemokine RANTES was induced within 5 days
after TBEV infection, and the expression levels also
remained elevated until the moribund state (Fig. 3a).
Below, the expression of RANTES upon TBEV infection
is characterized.
To confirm the protein array data, induction of
RANTES was examined by ELISA. Mediocre induction
of RANTES in response to TBEV infection was found as
early as 3 days post challenge (13.9 ± 0.6-fold increase).
Then, sustained up-regulation of RANTES in CNS was
observed from day 4 to day 8 after infection. Closely
mimicking the results from the protein array analysis, a
robust increase in RANTES protein expression was ob-
served on day 5 (226.6 ± 11.7-fold increase) and per-
sisted up to day 8 (258.8 ± 10.5-fold increase) p.i. within
the brain tissue. Interestingly, the induction pattern of
RANTES expression appeared to be coincided with the
dynamics of immune cell infiltration in the CNS. It is
noteworthy that no concomitant increase of RANTES
expression was recorded in tested peripheral tissues and
sera (Fig. 3b). Besides, the protein abundance for
RANTES (in pg/ml) in the brain was also greater than
those observed in tested peripheral tissues and sera fol-
lowing ic TBEV infection (data not shown). To strengthen
that the results obtained from 1-week-old mice are also
valid in adult mice, RANTES protein levels in the brain
and serum were also measured in mice aged 7–8 weeks
after ic infection with TBEV. By day 5 p.i., a slight increase
in RANTES expression occurred in the brain of adult
mice (2.9 ± 0.5-fold increase). TBEV infection caused a
dramatic increase in the level of brain RANTES on days 8
(36.4 ± 4.5-fold increase) or 11 (31.3 ± 4.6-fold increase)
p.i. compared to mock controls (Fig. 3c). There was no
obvious induction of RANTES production in the serum,
and RANTES level in the brain of TBEV-infected adult
mice was also significantly higher when compared to that
in the serum (data not shown). This higher RANTES con-
centration in the brain of virus-infected adult mice as
compared to that in the serum suggest potential localized
Fig. 1 Morbidity and mortality of mice infected with TBEV. a TBEV
burden in different tissues by ic route in mice. Litters of BALB/c mice
were challenged with TBEV WH2012 (103 TCID50s) by ic route. The
kinetics of virus replication and levels of TBEV were determined in
selected tissues of virus-infected mice at indicated time points (days
2, 5, and 8) by TCID50 assay. For each time point, the virus titers are
the average of four mice. Bars represent the means ± the standard
deviations of three independent experiments (n = 4 mice per group).
b Survival rates following ic inoculation with serial challenge doses
of TBEV. Survival curves were recorded for 12 days. Data shown are
pooled from three independent experiments (total of approximately
30 mice per group). c Survival rates following ip inoculation with
serial challenge doses of TBEV. Survival curves were recorded for
25 days. Data shown are pooled from three independent experiments
(total of approximately 30 mice per group)
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Fig. 2 Histopathological analyses for the TBEV-infected mice brain. The histopathological changes of PFA-fixed sections in cerebral cortex were
examined by HE staining at the denoted time points after TBEV or mock infection. Black arrows identify leukocytes infiltrating into the brain
tissues. The photomicrographs demonstrate representative images obtained from three independent experiments (n = 4 mice per group).
Bars, 100 μm
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inflammatory responses. Taken together, these observa-
tions suggest that TBEV induces a significant increase of
RANTES production within CNS, which is likely related
to the progression of neuroinflammatory responses.
Antagonizing RANTES slows down CNS disease
progression in TBEV-infected mice
Previous studies have demonstrated that TBEV induced
significant alterations in brain physiology that appeared
to closely parallel the pattern of RANTES expression.
To determine whether antagonizing the activity of this che-
mokine within CNS would affect disease progression,
virus-infected mice were treated with either Met-RANTES
or anti-RANTES mAb. As shown in Fig. 4a, b, all infected
vehicle, Met-RANTES, isotype control mAb, and anti-
RANTES mAb-treated mice eventually succumbed to
TBEV infection. However, both Met-RANTES and anti-
RANTES mAb-treated mice showed a significant delay in
mean time to death after infection, compared with
corresponding control groups. The mean survival time for
isotype control mAb-treated infected mice was approxi-
mately 7.1 days, while anti-RANTES mAb-treated mice
succumbed to mortality later after infection (mean days
until death, 10.0 days). TBEV-infected Met-RANTES-
treated mice lived an average of approximately 4 days
longer (mean days until death, 11.3), compared with virus-
Fig. 3 TBEV infection induces RANTES production within the brain of mice. a Expression of 40 inflammatory factors in the mice brain detected
by an inflammation Ab array assay. Representative photomicrographs demonstrate that TBEV infection stimulated RANTES (indicated by arrows)
expression. Data shown are pooled from three independent experiments (n = 4 mice per group). b Time course of TBEV-induced stimulation of
RANTES protein expression in different tissues. Bars represent the means ± the standard deviations of three independent experiments (n = 4 mice
per group). The fold changes in expression of RANTES in the brain of TBEV-infected mice were significantly higher when compared to those of
the peripheral tissues and sera on days 3, 4, 5, and 8 p.i. (*P < 0.05). c Fold changes of RANTES protein levels in the brain and serum of TBEV-infected
adult mice. Bars represent the means ± the standard deviations of three independent experiments (n = 4 mice per group). The fold changes in
expression of RANTES in the brain of TBEV-infected mice were significantly higher when compared to that of the sera on days 5, 8, and 11
p.i. (*P < 0.05)
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infected vehicle-treated mice (mean days until death, 7.2).
Moreover, TBEV-infected mice treated with Met-RANTES
(Fig. 4c) or anti-RANTES mAb (Fig. 4d) exhibited delayed
growth retardation, compared with virus-infected vehicle-
or isotype Ab-treated animals, respectively. The intensity
of symptoms increased gradually up to a moribund state,
at a much slower rate for TBEV-infected mice treated with
Met-RANTES or anti-RANTES mAb, compared with
vehicle- or isotype Ab-injected animals, respectively (data
not shown). These results suggest that antagonizing
RANTES within CNS affects disease progression following
lethal ic challenge with TBEV.
In an effort to identify the potential contributing fac-
tors to the enhanced survival of anti-RANTES-treated
mice, we assess virus replication in the brain of infected
mice. As shown in Fig. 4e, no significant difference was
observed in TBEV titer recovered from the brain of Met-
RANTES-treated mice compared with that in vehicle-
Fig. 4 Antagonizing RANTES within CNS extends the survival of mice after TBEV infection. Mice were treated with Met-RANTES, vehicle, anti-RANTES
mAb, or isotype-matched control Ab daily from day 2 to 8 after a primary TBEV infection. a Met-RANTES-treated mice exhibited a delay in mortality
following lethal TBEV challenge. Mortality in each group was monitored daily for 14 days. Data were pooled from three independent experiments
(total of approximately 18 mice per group). Statistical differences were evaluated using the Kaplan–Meier test for mortality. *P < 0.05, compared to
vehicle-treated mice. b Anti-RANTES mAb-treated mice exhibited a delay in mortality following lethal TBEV challenge. Mortality in each group was
monitored daily for 14 days. Data were pooled from three independent experiments (total of approximately 18 mice per group). *P < 0.05, compared
to isotype Ab-treated mice. c, d Body weight changes of mice were monitored daily. For each time point, the measured values are the average of the
surviving mice. Bars represent the means ± the standard deviations of three independent experiments (total of approximately 18 mice per group).
e Infectious virus in brain tissues. No significant difference in virus titers was observed at day 2, 5, or 8 between Met-RANTES-treated mice and vehicle-
injected mice or anti-RANTES mAb-treated and isotype Ab-injected mice. Bars represent the means ± the standard deviations of three independent
experiments (n = 4 mice per group). NS not significant. f Met-RANTES or anti-RANTES mAb treatment reduced inflammatory cell accumulation
(indicated by black arrows) in cerebral cortex sections, compared to results for vehicle- or isotype Ab-treated mice, respectively. The histopathological
changes of PFA-fixed sections in cerebral cortex were examined by HE staining on day 8 p.i. The photomicrographs demonstrate representative images
obtained from three independent experiments (n = 4 mice per group). Bars, 100 μm
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injected mice. On day 2, 5, and 8 p.i., virus titers in brain
tissue were also similar between the infected anti-
RANTES mAb-treated and isotype Ab-treated groups.
Morphologically, treatment of TBEV-infected mice with
either RANTES receptor antagonist Met-RANTES or
anti-RANTES mAb resulted in a significant decrease in
local infiltration of inflammatory cells. In addition, less
severe perivascular cuffing and hemorrhage within brains
after Met-RANTES or anti-RANTES mAb administration,
compared to the pathological manifestations present
within the cerebral cortex of vehicle or isotype Ab-treated
mice was found (Fig. 4f). Therefore, it is likely that block-
ade of RANTES within CNS reduced accumulation of
infiltrating cells and extended the survival of mice after
TBEV infection. Overall, our data highlight a potential
role for RANTES within CNS in affecting neuroinflamma-
tion during TBEV infection.
TBEV up-regulates RANTES production in human
brain-derived cells
The primary target of TBEV is the brain. To investigate
the mechanism by which TBEV induces RANTES in the
CNS, the ability of TBEV infection to trigger RANTES
expression in human brain-derived cell lines was assessed.
TBEV significantly induced RANTES production both at
the messenger RNA (mRNA) and protein levels in human
glioblastoma cells T98G at 24 h p.i. and reached a high
level at 72 h p.i. compared with mock-infected controls
(Fig. 5a, b). Human astrocytoma cells CCF-STTG1 and
neuroblastoma cells SK-N-SH were also capable of signifi-
cantly expressing RANTES in response to TBEV infection,
but the level of RANTES expression was generally much
lower than that in T98G cells (Fig. 5c–f ). To examine
whether TBEV infection induces RANTES expression in
primary CNS cells, further experiments were conducted
using HPDAs as a model. RANTES transcription was in-
duced by TBEV infection, with the increase started at 24 h
p.i. and peaked at 72 h p.i. (Fig. 5g). The protein levels of
RANTES reached the peak at 72 h p.i., and the pattern
was similar to that of the three cell lines described above
(Fig. 5h). In tested virus-infected brain cells, the up-
regulation of RANTES gene expression by TBEV was
likely replication dependent, since UV inactivation dra-
matically impaired the ability of TBEV to induce RANTES
mRNA expression and protein secretion. To reveal the
kinetics of virus replication, virus titers were measured for
the indicated time points by TCID50 assay. As shown in
Fig. 5i, TBEV replicated efficiently in all cell lines tested.
Increasing titers of infectious virus were observed after
24 h p.i., and the maximum titer of virus was attained
after 72 h p.i. Given the above-described RANTES expres-
sion profile, its production appeared to be significantly in-
duced at time points that coincided with significant virus
replication in human brain-derived cells. It was also found
that viral replication was coupled to RANTES up-
regulation in alveolar epithelial A549 cells (Additional
file 1: Figure S1A–C). However, though TBEV could
replicate in human monocytic cell line THP-1, RANTES
production was not significantly induced after infection of
this cell line, demonstrating a cell type-specific pattern of
RANTES production (Additional file 1: Figure S1D–F).
To conclude, the human brain cells are capable of signifi-
cantly producing RANTES upon TBEV infection, al-
though the level of induced RANTES may vary depending
on the cell type.
We further determined the chemotactic activity of the
secreted RANTES from TBEV-infected T98G cells using
a transwell migration assay. Supernatants from these
cultures were more potent in chemoattracting THP-1
cells, compared with those from uninfected control cells.
Notably, the chemoattractant activities of these condi-
tioned medium were largely reduced when incubated
with anti-hRANTES Ab, suggesting that RANTES is a
functionally active chemotactic component secreted by
TBEV-infected T98G cells (Fig. 5j).
TBEV-induced RANTES expression is mediated through
transactivation of RANTES promoter
To determine whether TBEV infection transactivates the
RANTES promoter, a reporter plasmid pGL-220 which
contains the sequence from nucleotides −220 to −55
(relative to the mRNA start site) was co-transfected with
pRL-TK into T98G cells, followed by TBEV infection.
T98G was chosen as a cell model due to its relatively
high transfection efficiency and the ability of the cells to
produce high levels of RANTES transcripts upon TBEV
infection. As shown in Fig. 6a, TBEV infection of trans-
fected T98G cells induced a dose-dependent increase of
luciferase activity, with the maximal stimulation detected
at an MOI of 5. UV-inactivated virus was not capable of
inducing RANTES transcription, confirming our previous
observation that RANTES induction requires productive
TBEV infection. The TBEV-induced promoter activation
was also time-dependent, with the increase of luciferase
activity started at 24 h and reached the highest levels at
48 h p.i. (Fig. 6b).
The RANTES promoter comprises five pivotal binding
sites for the transcription factors CRE, ISRE, NF–IL-6,
NF-kB1, and NF-kB2 (Fig. 6c) [29]. To determine the
contributions of individual cis regulatory elements in
conferring responsiveness to TBEV infection, we tested
the impact of mutations at these sites on TBEV-induced
RANTES production. As shown in Fig. 6d, mutation of
the ISRE site not only affected the promoter basal activity
but also nearly completely abolished TBEV-induced
RANTES promoter activation. Mutation of the NF-kB1 or
NF-kB2 site also reduced the basal activity, with the latter
decreasing the TBEV-induced luciferase activity, although
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Fig. 5 RANTES is up-regulated in TBEV-infected human brain-derived cells. T98G (a, b), CCF-STTG1 (c, d), and SK-N-SH (e, f) cells and HPDAs (g and h)
were inoculated with medium alone, TBEV, or UV-inactivated TBEV at an MOI of 1. Total RNA was extracted from cell lysates at 6, 24, 48, and 72 h post
inoculation. RANTES mRNA was quantified by real-time PCR (a, c, e, and g), and results were normalized to GAPDH and expressed as fold induction
over medium alone at 6 h post inoculation. Supernatants were harvested at 6, 24, 48, and 72 h post inoculation, and levels of RANTES (pg/mL) released
were determined by ELISA (b, d, f, and h). Bars represent the means ± the standard deviations of three independent experiments. *P < 0.05 versus
mock control. i TBEV replication kinetics in human brain cells. T98G, CCF-STTG1, and SK-N-SH cells and HPDAs were infected with TBEV at an MOI of 1.
Supernatants were collected at indicated time points, and virus titers were determined by TCID50 assay. The results are presented as the means ±
standard deviations obtained from three independent experiments. j Neutralization of RANTES in T98G cell supernatants with specific anti-hRANTES
Ab (αRANTES) reduced THP-1 cell migration. The same amount of normal goat IgG was used as controls. Data are expressed as the percentages of
migrated cells in total cells added and presented as means ± the standard deviations of three independent experiments. *P < 0.05 versus control;
#P < 0.05 versus TBEV-infected alone. Statistical analysis was performed by Student’s t test
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to a much lesser extent. Taken together, these data
indicate that ISRE element of RANTES promoter is
possibly mainly responsible for TBEV-induced RANTES
expression.
TBEV-induced RANTES expression is mediated by
activation of IRF-3 signaling pathway
To clarify the essential role of ISRE, the effects of ISRE-
binding IRF-3 and IRF-7 transcription factors lacking
their DNA-binding domains (mutants IRF-3ΔN and
IRF-7ΔN, respectively) on TBEV-induced RANTES
expression were determined. In reporter gene assays,
compared with corresponding controls, over-expression
of IRF-3ΔN dramatically inhibited the ability of TBEV in
activating RANTES gene transcription, whereas co-
transfection with IRF-7ΔN in TBEV-infected T98G cells
did not have such impact (Fig. 6a). Moreover, over-
expression of a nondegradable IkBα mutant (mIkBα)
had no effect on activation of the RANTES promoter
(Fig. 6b).
To determine whether TBEV trigger RANTES expres-
sion by directly inducing activation of known IRF-3
pathway component, we performed Western blot ana-
lysis to detect the levels of endogenous RIG-I, MDA5,
TLR3, p-TBK-1, p-inhibitor-kB kinase epsilon (IKKε),
and p-IRF-3 following infection of T98G cells with
TBEV. As depicted in Fig. 6c, TBEV induced up-
regulation of RIG-I and MDA5 as early as by 24 h p.i.,
whereas no detectable TLR3 and p-IKKε were seen dur-
ing the process of infection in T98G cells (data not
shown). Concomitantly, virus replication also activates
specific virus-induced kinase TBK-1, which regulates the
phosphorylation and thus the activation of IRF-3 [34].
Indeed, phosphorylated forms of IRF-3 (p-IRF-3) were
clearly detectable by 24 h p.i. However, we failed to de-
tect a significant decrease in the level of endogenous
IkBα, which is a hallmark of IkBα degradation and NF-
kB activation.
The abovementioned results indicate that the expres-
sion of both RIG-I and MDA5 is greatly enhanced in
response to TBEV infection. To explore the role of these
proteins in modulation of virus-induced RANTES
production, we performed knockdown of RIG-I and
MDA5 using siRNA. As shown in Fig. 7d, Ctrl siRNA
did not affect the virus-induced activation. Knockdown
of either RIG-I or MDA5 led to a significant decrease in
the amount of RANTES chemokine production under
the experimental conditions. These results indicate the
Fig. 6 TBEV infection results in the induction of RANTES promoter activity. a T98G cells were co-transfected with pGL2-220 and pRL-TK, followed
by UV-inactivated TBEV or TBEV infection at different MOIs; 24 h p.i. cells were harvested to measure luciferase activity. The results are expressed
as fold induction of RANTES promoter activity relative to the basal level. *P < 0.05 versus mock control. b T98G cells were co-transfected with
pGL2-220 and pRL-TK, followed by TBEV infection at an MOI of 0.1. At indicated times p.i., cells were harvested to measure luciferase activity. The results
are expressed as fold induction of RANTES promoter activity relative to the basal level. *P < 0.05 versus mock control. c Schematic representation of the
RANTES promoter constructs [29]. Locations of the putative binding sites for CRE, ISRE, NF-IL-6, and NF-kB are illustrated. Numbering is relative to the
transcription initiation site. d Effect of site mutations in the RANTES promoter sequence on TBEV-inducible activity. T98G cells were transiently trans-
fected with site-mutated (Mut) plasmids of the pGL2-220 RANTES promoter and infected with TBEV for 36 h. The results are expressed as fold induction
of RANTES promoter activity relative to the basal level. Bars represent the means ± the standard deviations of three independent experiments. *P < 0.05
compared with pGL2-220 plus TBEV infection
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involvement of endogenous RIG-I and MDA5 in the up-
regulation of RANTES upon TBEV infection in T98G cells.
To confirm the actual contribution of TBK-1/IRF-3
module to the TBEV-induced RANTES expression, T98G
cells were treated with BX795, an inhibitor blocking
TBK1- and IKKε-mediated activation of IRF-3, followed by
TBEV infection. BX795 significantly blocked the TBEV-
induced phosphorylation of IRF-3 at Ser396. Furthermore,
secretion of RANTES from T98G and CCF-STTG1 cells
was significantly blocked in the presence of BX795. In con-
trast, treatment with MG132, a potent inhibitor of NF-kB
activation, had no effect on RANTES release in virus-
infected cells. Therefore, it appears that TBEV-induced
production of RANTES is unlikely dependent on the NF-
kB signaling pathway (Fig. 7e). It should be noted that both
BX795 and MG132 did not significantly block virus repli-
cation under the conditions of the experiment (Additional
file 2: Figure S2). These results suggest that activation of
IRF-3 signaling pathway is most likely to be involved in the
TBEV-induced RANTES expression.
Discussion
To focus our study on specific immune mechanisms
involved in CNS response to viral infection rather than
Fig. 7 TBEV-induced RANTES expression is mediated by activation of IRF-3 pathway. a T98G cells were co-transfected with pGL2-220 and pRL-TK
together with an empty vector or a dominant-negative mutant IRF-3 (IRF-3ΔN) or IRF-7 (IRF-7ΔN) and infected or uninfected with TBEV at an MOI
of 1. Cells were harvested at 24 h post infection to measure luciferase activity. The results are expressed as fold induction of RANTES promoter
activity relative to the basal level. Bars represent the means ± the standard deviations of three independent experiments. b The experiments were
performed similar to those described in a except that a dominant-negative mutant IkBα plasmid (mIkBα) was used. Bars represent the means ±
the standard deviations of three independent experiments. c Western blot analysis of phosphorylation state of IRF-3 in TBEV-infected cells.
Whole-cell lysates were recovered from mock- and TBEV-infected T98G cells over a 48 h time course, and Western blot analysis was performed to
examine levels of p-IRF-3, IRF-3, p-TBK1, TBK1, RIG-I, MDA5, IkBα, and β-actin. Three independent experiments were performed, and one representative
result was shown. d Effect of RIG-I or MDA5 siRNA on RANTES expression in TBEV-infected cells. T98G cells were transfected with indicated siRNA. After
16-h incubation, the cells were mock-infected or TBEV-infected (MOI = 1) for 24 h. Supernatants were harvested and analyzed for RANTES protein
expression (pg/ml) by ELISA (upper panel). Bars represent the means ± the standard deviations of three independent experiments. Expression of RIG-I
or MDA5 proteins was assessed by Western blot analysis (lower panel). β-actin serves as a loading control. One representative result of three is shown.
e T98G and CCF-STTG1 cells were infected with TBEV at an MOI of 1, followed by treatment with BX795, MG132, or DMSO vehicle in the absence of
serum for 36 h. Levels of RANTES (pg/ml) released were determined by ELISA (upper panel). Bars represent the means ± the standard deviations of three
independent experiments. Western blot was performed to examine levels of p-IRF-3 or IRF-3 (lower panel). One representative result of three is shown.
*P < 0.05 indicates significant difference between groups tested. NS not significant
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on aspects of extracerebral infection and neuroinvasion,
we challenged mice with TBEV via ic route. Pathological
analysis of CNS tissues from moribund mice demon-
strated marked leukocytes infiltration, which is consistent
with autopsy studies on human patients infected with
TBEV [7, 8]. Once in the CNS, there are three possible
mechanisms by which flaviviruses induce brain tissue de-
struction leading to the clinical manifestations of disease.
Virus infection may directly lead to neuronal cell injury
and virus-induced neuroinflammatory responses may
cause neuronal death, or both [9, 35]. CNS pathology of
TBEV is considered to be, at least in part, due to viral in-
fection of corresponding cells, since virus induces both
apoptosis and necrosis in human neural cells and also in
mouse and monkey brain neurons [36–39]. However,
there is a growing body of evidence indicating that abnor-
mal immune response is one major cause of tissue damage
and fatal encephalitis [40]. TBEV infection of the CNS has
been shown to result in markedly enhanced leukocyte mi-
gration into the brain tissue and immune-mediated BBB
breakdown, both of which corresponded with excessive
expression of chemokines and cytokines in the brain
parenchyma [41]. Using an Ab array that detects 40 im-
mune factors, we observed that TBEV infection stimulated
several inflammatory mediators, including chemokine
RANTES and MCP-1 and cytokines IL-12p40p70, IL-
12p70, and IL-4. Our findings are in line with previous
studies on chemokine and cytokine profiles of mouse
CNS infected with the Neudoerfl strain of TBEV-Eu sub-
type or the Sofjin strain of TBEV-FE subtype, demonstrat-
ing a common induction pattern of these immune
mediators among TBEV infection [41, 42]. It is note-
worthy that we did not observe a significant increase of
certain proinflammatory cytokines including tumor necro-
sis factor (TNF)-α and IL-6. This could be due to the
sensitivity of the protein array adopted, various immune
responses of distinct mouse models, or the difference in
inducing specific cytokines by different TBEV strains.
These need to be clarified in future studies.
During TBEV infection, the expression of proinflamma-
tory molecules may contribute to the influx of peripheral
lymphocytes in the brain as well as to the severity of the
encephalitis [7, 8, 14]. In this report, we found that CC
chemokine RANTES was one of the most rapidly and
rigorously induced molecule in the CNS during TBEV
infection. The increasing level of RANTES expression
between 3 and 8 days p.i. was shown to be consistent with
increasing immune cell infiltrates and neuroinflammation
in virus-infected 1-week-old mice. Besides, ic infection of
TBEV in adult mice also induced a significant increase in
the level of RANTES within CNS, but not in sera. These
findings suggest that the capability of inducing RANTES
expression by TBEV infection seems not to depend on age
of the mouse. Even though the neonatal immune system
is somewhat less mature than those of adult, neonates are
not immune privileged, especially under high inflamma-
tory conditions. A large body of evidence indicated that
the mouse neonatal immune system is capable of mount-
ing virus-specific T cell-based immune responses, as well
as protective memory and Ab responses [43–45]. In other
studies, increased expression of RANTES was found in
neonatal mice after infection with viruses such as coxsack-
ievirus B3 [46] and influenza virus [47] or protozoan
parasite such as Cryptosporidium parvum [48]. It should
be noted that though neonatal mice are a relatively high-
sensitive model for the study of flavivirus infections,
peripheral administration of WH2012 strain via either ip,
sc [18], or im (data not shown) route did not lead to
100 % lethality. These data indicate that WH2012 strain
used in this study is less pathogenic, as compared with
some highly virulent TBEV isolates, such as strain Hypr
[49] and strain Sofjin [50].
RANTES is usually significantly induced following
viral infection, and its production represents a character-
istic of neuroinflammation [51]. It has been reported
that several viruses including human immunodeficiency
virus type 1 (HIV-1), herpes simplex virus-1 (HSV-1),
Japanese encephalitis virus (JEV), mouse hepatitis virus
(MHV), and rabies virus (RABV) can up-regulate
RANTES production within CNS [52–56]. Moreover, we
demonstrated a TBEV-induced robust expression of
RANTES in human brain-derived cell cultures that reca-
pitulated the cell types normally found in the brain includ-
ing neurons, astrocytes, and microglia. It is worth noting
that RANTES was dramatically increased neither in tested
peripheral tissues nor in sera. Similar findings were previ-
ously reported in human cases of TBE, showing that
RANTES was significantly increased in CSF, but not in
sera [12, 14]. Furthermore, our in vitro culture systems
showed that TBEV induces the production of RANTES
which is functionally active in recruiting human mono-
cytic cells. Therefore, the strikingly high expression of
RANTES within CNS is likely to be one of the mediators
that form a concentration gradient in the brain during
TBEV infection. For describing a specific involvement of
RANTES in experimental TBE, future research should
define the activated cell types which will be recruited into
CNS after RANTES production upon TBEV infection.
In this work, we observed that treatment of mice with
Met-RANTES or anti-RANTES mAb prolonged survival
and decreased cellular infiltrates in the brain. In agree-
ment with our study, a previous report showed that, in a
severe herpes simplex encephalitis mouse model, treat-
ment with either Met-RANTES or anti-RANTES mAb
decreased leukocyte recruitment into the brain of HSV-1-
infected mice [54]. Moreover, Met-RANTES treatment
significantly reduced proinflammatory chemokine or cyto-
kine production in the CNS and prolonged survival time
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of the mice after RABV infection [56]. Considering
the important role of RANTES in exerting a potent
chemotactic effect on both monocytes and T cells,
our data suggest that both immune cells infiltrate
reduction and survival extension in treated TBEV-
infected mice was, at least in part, correlated with the
blockade of RANTES alone. Early studies demon-
strated the importance of CCR5, which is one of the
receptors of RANTES, as a protective factor in the
context of flaviviral infections. With the use of knock-
out mice, it was demonstrated that CCR5 deficiency
reduced immune cell infiltration of the CNS and in-
creased mortality after peripheral inoculation of WNV
[57] or JEV [58]. In humans, homozygosity for the
CCR5Δ32 allele is associated with the predisposition
to the clinical TBE in Lithuanian people [59, 60], but
not Russian people [61]. These findings suggest that
CCR5 deficiency is probably relevant to a weakened
immune defense against evading flaviviruses. However,
it can be speculated that direct administration of a
receptor antagonist to the brain is clearly different to
a systemic loss of the receptor, which may be ascribes
to significant difference between the immune re-
sponse elicited in the CNS and the response in the
periphery. Moreover, it would be expected that antag-
onizing RANTES alone may differ from blockade of
CCR5, in which both binding of a number of chemokines
and recruitment of main immune cell types may be
affected. In this study, we were not able to draw any
conclusions on relationships between disease severities of
TBE and a functional RANTES-CCR5 axis. Future studies
with conditional RANTES and CCR5 knockout mouse
models may help delineating the pathogenic mechanisms
of the disease.
It is worth noting that despite remarkable prolongation
of survival times of infected mice after Met-RANTES
and anti-RANTES mAb treatments, both strategies
led to no change in viral burdens following a high in-
oculum of TBEV injection in the brain. Therefore, it
seems that blockade of RANTES within CNS appears
to result in alteration of the immune/inflammatory
response, rather than a simple modulation of increase
or decrease in the level of TBEV infection. Since both
viral infection and host immune responses likely
contribute to the pathogenesis of TBE, enhancement
of the antiviral activity against TBEV and amelioration
of the neuroinflammatory response may theoretically
help in reducing the severity of the disease. Further
studies are needed to determine whether concomitant
administration of antivirus drugs together with anti-
inflammatory agents could offer an additive beneficial
effect on TBE. With respect to other chemokines
induced by TBEV, antagonizing MCP-1 within CNS
did not significantly ameliorate TBEV infection (data
not shown). However, future research is warranted to
explore whether some of the detected or as yet un-
identified immune mediators contribute individually
and synergistically to neuroinflammatory responses in
the process of TBEV infection.
In this study, we found that TBEV infection could
induce RANTES production in human brain-derived
cell lines and primary progenitor-derived astrocytes in
vitro. This up-regulation was not detectable as early
as 6 h p.i., and measurable RANTES mRNA expres-
sion and protein release only occurred between 24
and 48 h p.i. The results observed here are reminis-
cent of some previous studies on delay of IFN
induction upon TBEV infection. At early stages of
infection, viral double-stranded RNA (dsRNA) was
mainly found within ER-derived vesicles, thus to be
largely unavailable for cytoplasmic pattern recognition
receptors (PRR) [62, 63]. Similarly, the mechanism
behind the delay of RANTES production might also
be that TBEV induces replication vesicles, thereby
delaying the detection of viral dsRNA by PRR sensors.
Although it is known that TBEV infection can induce
RANTES production in vivo and in vitro, the under-
lying mechanism contributing to the induction of
RANTES after TBEV infection has not been explored.
Using brain-derived cells as a model, we demon-
strated that TBEV infection activated the RANTES
promoter in both time- and dose-dependent manners.
It is generally believed that expression of many of the
chemokine genes is regulated primarily at the level of
transcription, and their promoter regions contain rec-
ognition sites for virus-activated transcription factors
[64]. Binding sites for a wide variety of transcription fac-
tors annotated within the RANTES promoter include IRFs,
NF-kB, CCAAT/enhancer-binding protein (C/EBP), and
cAMP response element-binding protein (CREB)/activating
protein 1 (AP-1) [29, 65]. These transcription factors
have been shown to contribute to the differential
regulation of RANTES gene expression, depending on
the virus and the cell type [53, 66–69]. We revealed in this
study that TBEV-induced transcription of RANTES is
mainly mediated by activation of the IRF-3 pathway. This
conclusion is based on several lines of evidence: (i) muta-
tion of the ISRE site almost completely abolished TBEV-
induced promoter activation; (ii) over-expression of IRF-3,
but not IRF-7 or IkBα dominant-negative mutant,
efficiently inhibited TBEV-induced RANTES production;
(iii) TBEV infection triggered the phosphorylation of
endogenous IRF-3 in a time-dependent manner; and (iv)
addition of inhibitor targeting TBK1–IRF-3 signaling
pathway considerably reduced RANTES production in
T98G and CCF-CTTG1 cells.
Flavivirus infections produce virus replicative inter-
mediate dsRNA, which could be detected by the
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cytoplasmic RNA sensor RIG-I and MDA5 [70, 71].
By interacting with mitochondrial adapter protein
mitochondrial antiviral signaling protein (MAVS),
RIG-I/MDA5 directs the activation of TBK1 and IKKε
[72–74]. Activated TBK1 mediates IRF-3 phosphoryl-
ation, which ultimately leads to the transcription of
type I IFN and other cellular genes with host defense
functions. For instance, phosphorylation of IRF-3 can
directly stimulate RANTES transcription [66]. In
other scenarios, IRF-3 is also of particular importance
in synergistically promoting RANTES expression, together
with NF-kB activation [67, 75]. In the current study, we
showed that RIG-I/MDA5- and TBK1-directed IRF-3
phosphorylation is critical for TBEV-induced RANTES
expression. In contrast, NF-kB pathway did not ap-
pear to play an essential role in stimulating RANTES
transcription following TBEV infection, as evidenced
by both transfection experiments with dominant-
negative mutants of IkBα and pretreatment studies
with NF-kB inhibitor MG132. It is conceivable that
the pathways leading to activation of IRF-3 may
distinct from the potential pathways that stimulate
NF-kB in our system. Since ISRE promoters are
activated by cellular IRFs but do not require NF-kB
activation, we speculate that IRF-3-mediated activa-
tion of the ISRE is a major determinant of the induc-
tion of RANTES transcription after TBEV infection.
It is important to note that other IRFs, exemplified
by IRF1, have been shown to contribute to RANTES
induction after respiratory syncytial virus (RSV) infec-
tion [29]. Thus, though our results support the idea
that IRF3 is involved in RANTES expression during
TBEV infection, the potential role for other IRFs
could not be excluded. Future studies will be import-
ant and interesting to clarify whether a somewhat
activated form of other IRFs could, possibly in syn-
ergy with IRF3 signaling, result in the induction of
RANTES after TBEV infection.
Conclusions
In summary, our study shows that TBEV-induced in-
flammatory responses in the CNS seem to be associated
with a robust production of chemokines and cytokines,
of which RANTES is a strong candidate for recruiting
immune cells to brain tissues. In addition, our findings
reveal the molecular pathway of TBEV-mediated induc-
tion of RANTES, involving activation of RIG-I/MDA5
and TBK1, with subsequent activation of IRF-3 resulting
in increased RANTES expression. These findings expand
the current knowledge of the role of specific chemokines
during TBEV infection and render RANTES particularly
interesting for further investigations in human and ex-
perimental TBE.
Additional files
Additional file 1: Figure S1. Expression of RANTES in TBEV-infected
A549 and THP-1 cells. A549 (A and B) and THP-1 cells (D and E) were
inoculated with medium alone, TBEV, or UV-inactivated TBEV at an MOI
of 1. Total RNA was extracted from cell lysates at 6, 24, 48, and 72 h post
inoculation. RANTES mRNA was quantified by real-time PCR (A and D),
and results were normalized to GAPDH and expressed as fold induction
over medium alone at 6 h post inoculation. Supernatants were harvested
at 6, 24, 48, and 72 h post inoculation, and levels of RANTES (pg/mL)
released were determined by ELISA (B and E). Bars represent the means
± the standard deviations of three independent experiments. *P < 0.05
versus mock control. A549 (C) and THP-1 cells (F) were infected with TBEV
at an MOI of 1. Supernatants were collected at indicated time points, and
virus titers were determined by TCID50 assay. The results are presented as
the means ± standard deviations obtained from three independent
experiments. *P < 0.05 versus mock control. NS = not significant.
(TIF 372 kb)
Additional file 2: Figure S2. Impact of BX795 or MG132 treatment on
TBEV replication. T98G or CCF-STTG1 cells were inoculated with TBEV
(MOI = 1), followed by treatment with BX795 (2 μM), MG132 (3 μM), or
DMSO vehicle in the absence of serum for 36 h. Supernatants were
harvested, and virus infectivity was determined by estimation of the
TCID50 as described above. NS = not significant. (TIF 83 kb)
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